Determination of tobramycin serum concentrations in ICU patients treated with SDD: a prospective study.

Completed

• Conditions: profylaxe optreden infecties; SDD; tobramycine absorption; 10004018

• Registration Number: NL-OMON43386
• Lead Sponsor: Martini Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2016-11-23
• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

- Signed informed consent
- Patient has to lie on the ICU or Medium Care - ICU
- Patient has to use SDD

Exclusion Criteria

- Patients that are admitted to the burns IC
- Patients concurrently or within 72 hours prior to SDD treatment receiving tobramycin administered parenterally or pulmonary
- Patients who aren't treated with the regular schedule

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint of this study is the achievement of a high (> 1.0 mg / L)<br /><br>tobramycin serum concentration during the use of SDD.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints of the study are:<br /><br>Identification of risk factors that contribute to high systemic serum<br /><br>tobramycin concentrations. To this end, we extract data from the patient record<br /><br>in soft chip. With the data extraction the criteria of the National Intensive<br /><br>Care Evaluation (NICE) will be used as much as possible.</p><br>